Nightingale Health is a technology company built around blood analysis. The company tries with new technology, which initially seems competitive, to break into a conservative health care customer base, where achieving commercial success and its possible timing are, however, very uncertain. Despite the high long-term potential, we still have to wait for the signs of success and believe that positive share price drivers are still scarce. We, therefore, believe that the risk/return ratio will be weak over the next 12 months.